Skip to main content

We grow faster than our markets, and we manufacture most of what we sell.

Scroll down

Polpharma Group has compounded revenue at almost 12% a year since 2021, it leads prescription and consumer health in its home markets, and three quarters of sales come from its own plants.

€1.3B+
Revenue annually
2025 FY
+11.9%
Revenue CAGR
2021-2025
>10%
Growth ambition
going forward
75%
Sales revenue generated
by internal production

Where are we heading?

Our direction follows where medicine and demography are heading, ahead of where we already sell. We lead in Poland and Kazakhstan, we are building a position across Central Asia and the Caucasus, and we are extending the same model into Europe: own production, partnered distribution, and a portfolio moving from generics into biosimilars and oligonucleotides.

strategic priorities

Double-digit growth, every year, ahead of the market.

Goals we set for ourselves:

Grow to expand

Growth is the priority the other four serve. We have outgrown our markets for years, and the strategy is built to keep that lead as we scale.
Extend the platform.
Across Europe and globally, market by market.
Expand the portfolio.
From generics into biosimilars and oligonucleotides.
Deepen the therapeutic franchises.
Build on leadership in the areas where we already have scale.
Grow revenue.
Partnered and in-licensed, alongside our own brands.

Compete to win

Leadership is held launch by launch, in the categories and countries where the group already leads.

Innovate to speed up

Differentiated science shortens the distance from molecule to market and opens categories others cannot enter.

Enablers that keep us delivering them:

Transform to progress

Digitising operations and decision-making across the group, from plant to commercial.

Culture to perform

An entrepreneurial, scientific culture that performs under private ownership.

We are a regional leader, and a global partner.

14 direct markets across Europe and Central Asia, partner-led distribution in 40+ markets, and B2B licensing across more than 100 markets.

our markets

Learn more

integrated value chain

We are an integrated pharmaceutical platform, from synthesis to the patient.

You can work with us at one point on the value chain or across all of it. Each capability runs to the same standards and connects to the next, so a partnership in one area has the rest of the platform behind it.

Previous
Next

01 Research

& Development

We develop active substances and finished dosage forms across our own pipeline and with partners - supported by R&D centers across Europe and Central Asia.

6 R&D centers

37 doctorates
€0.5B+ invested since 2000

Research
& Development

02 Active Pharmaceutical
Ingredients

Forty APIs in commercial production, each with a complete DMF stack. From standard chemistry to high-potent compounds, oligonucleotides, and cryogenic synthesis.

65+ patents granted
70+ APIs in portfolio

FDA-approved, EU GMP-certified

Active Pharmaceutical Ingredients

03 Finished Dosage
Forms

Every major form, at scale: solid, sterile, ophthalmic, inhaled, injectables, and more. Four hundred million packs a year, across our own brands and partner programs.

6B tablets

979M capsules

226M ampoules per year

Finished Dosage Forms

04 Commercialisation

& Market Access

Out-licensing and in-licensing programs into hundreds of markets. Own brands across CEE, CIS, Central Asia, and Germany. We lead the categories where we compete.

14+ Markets directly

40+ markets via partners

100+ Markets licenced

Commercialisation
& Market Access

portfolio

Four therapeutic franchises carry our portfolio.

Cardio-diabetes leads at over €190 million in sales, built from more than thirty brands. Anti-infectives, alimentary and central-nervous-system franchises each clear €80 million. In Poland the group is the ophthalmic leader and an emerging player in respiratory inhalers.

Franchize size by annual net sales

2025 · approximate
Cardio-diabetes

30+ BRANDS ABOVE €1M

> 190M
Anti-infectives

30+ BRANDS ABOVE €1M

> 85M
Alimentary

30+ BRANDS ABOVE €1M

> 85M
Central nervous system

30+ BRANDS ABOVE €1M

> 85M
Beyond the core, the portfolio runs from first-to-market generics and value-added medicines to biosimilars, hospital tenders and consumer-health brands.
See our portfolio

Security of supply

Where we compete, we already lead.

We extend positions we already hold, in the categories and countries where we are first.

No 1.
Market position
First in prescription and consumer health in Poland and Kazakhstan, and third and second in Ukraine. The plan rests on markets we already lead.
First
1st to market
First in Poland when exclusivity ended on apixaban and dapagliflozin, and first to bring a respiratory dry-powder inhaler to the EU.
15+
Lifecycle management
More than fifteen prescription brands have been switched into consumer health, extending product life well beyond patent expiry.
Top 20
Multi-regional scale
We rank among the twenty largest makers of generic medicines worldwide. The leadership we hold in our home markets is built on that base.

the growth

Our revenue has compounded at almost 12% a year since 2021.

The plan to 2030 holds that rate and takes group revenue above €2 billion. The same engine that delivered the last four years carries the next five.

Group revenue · €m

2B
1.5B
1B
0.5B
0
€
0
BN
2021
€
0
BN
2022
€
0
BN
2023
€
0
BN
2024
€
0
BN
2025
>€
0
BN
2030
Illustrative trajectory. Revenue CAGR +11.9% p.a. (2021–25); B2C +10.9%, B2B +10.5%. 2030 is the stated ambition.

Growth engines

Balanced portfolio, driven by new launches

A balanced book across prescription, consumer health and hospital, refreshed by a steady cadence of launches.

Hybrid commercial model

A customer-oriented consumer-health business alongside Rx, combining direct presence with B2B reach.

Partnership-driven business model

More than a fifth of revenue comes through long-term partner companies.

Geographic expansion & bolt-on M&A

New regions and selective acquisitions extend the platform’s footprint.

partnership

Built for partners.

Partnership is our core business, and a partner can enter the platform at any point: commercial licensing, active-ingredient supply, or contract manufacturing.

entering the market

Full pan-EU rights

We acquire full European rights with sub-licensing: direct commercialisation through its own structure across Central & Eastern Europe, and strategic sub-licensing to top European players via the B2B network.
entering the market

Agency model

We act as exclusive out-licensing agent in the EU - representing a partner’s portfolio and securing licensing deals through its network of multinationals and local champions.
industrial sypply

Active ingredients

We supply our own active ingredients, produced in Poland since 1951, sold across 65+ markets and recognised by the FDA, EMA and EDQM.
industrial supply

Contract manufacturing

We manufacture for partners across forms under EU-GMP, selling capacity and formulation know-how from our own plants.
20%+
Of revenue
generated through long-term parnerships
100+
Long-term partners
who source products from us
80+
Markets
where our products are sold
60+
Partnership deals
closed every year

partner with the gorup

Bring us a product, a market, or a manufacturing challenge.

“Polpharma Group enables partners to succeed.”

Explore partnerships
Start the conversation